Recordati
Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 3,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey and in the United States of America. A field force of more than 1,700 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2012 was € 828.3 million, operating income was € 167.0 million and net income was € 118.5 million.
Pro Farma offers medicinal products in selected indication areas and provides a range of services for pharmaceutical companies both in Switzerland and beyond.
Italchimici Spa, along with its subsidiaries, produces and supplies raw materials.
Casen Fleet is a pharmaceutical manufacturer based in Madrid, Spain, focusing on the development, clinical research, production, and marketing of products primarily in gastroenterology and women's health. The company's facility in Zaragoza spans 23,000 square meters and has undergone significant expansions and renovations since its establishment in 1985, with substantial upgrades completed in 2002 and the addition of a new laboratory for product development finalized in 2007. Casen Fleet is dedicated to creating specialist endorsed products that cater to the specific needs of its target markets.
Opalia Pharma S.A., established in 1988 and based in Ariana, Tunisia, specializes in the manufacture and marketing of generic pharmaceutical products. The company focuses on therapeutic areas such as dermatology, gastrointestinal, and respiratory diseases, offering a range of medicinal forms including liquids, creams, ointments, gels, suppositories, and pessaries. In addition to its manufacturing capabilities, Opalia Pharma provides various services, including the development and procurement of components, regulatory compliance, and pharmaceutical release. The company also engages in galenical and analytical development, offering services such as formulation, primary packaging, and the production of experimental batches. As of 2014, Opalia Pharma operates as a subsidiary of Recordati Industria Chimica e Farmaceutica S.p.A.
Farma-Projekt Sp. z o.o. produces various dietary supplements. Its products include Gastro Up, a dietary supplement for the functioning of digestive tract; Inhepax.
Orphan Europe SARL is a pharmaceutical company that specializes in the development of orphan medicinal products aimed at treating rare metabolic disorders. The company's portfolio includes several key products, such as Cystadane, Cystagon, Normosang, and Wilzin, which provide patients with essential treatment options for their specific health needs. By focusing on orphan drugs, Orphan Europe addresses the challenges faced by individuals with rare diseases, ensuring they have access to vital therapies under one umbrella.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.